Summary of COVID-19 iodine studies

1. Traksel et al., Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial

141 patient iodine late treatment RCT: 10% higher mortality (p=0.83), 34% lower ventilation (p=0.44), and 30% lower ICU admission (p=0.46).
RCT 141 hospitalized COVID-19 patients showing no significant difference in mortality or ICU admission with 12.5 mg daily oral iodine for 8 days. Exploratory analysis found patients receiving iodine had significantly shorter ICU stays.
Feb 2026, PLOS One, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0341126, https://c19p.org/traksel